Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

We were in the home­stretch for our an­nu­al 20 un­der 40 project when the pan­dem­ic hit the US. On March 8, I can­celed my train tick­ets to Boston to meet with nom­i­nees Ja­son Kel­ly at Gink­go and David Cheng. The next day was the first warm day in New York City, and the streets and parks were lit­tered with jog­gers and fam­i­lies out chat­ting in shrill, vol­u­ble tones af­ter three months cooped in the cold. I spoke ami­ably on the phone with Otel­lo Stam­pac­chia about how biotech was adapt­ing and about his fam­i­ly in Italy, the cri­sis there and the cri­sis com­ing. The WHO de­clared a pan­dem­ic two days lat­er. Soon, no one was out.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER